HX-100

HX-100 is a highly selective, potent small molecule inhibitor of the Transient Receptor Potential cation channel subfamily A member 1 (TRPA1). It was developed by Hydra Biosciences for the treatment of painful diabetic neuropathy and allergic asthma. The drug acts by inhibiting TRPA1, a novel target implicated in pain and inflammatory pathways. Preclinical studies have shown that TRPA1 inhibitors like HX-100 demonstrate efficacy in models of pain, pulmonary diseases, and dermatological conditions. The compound is orally bioavailable and designed to provide robust efficacy without abuse potential due to limited expression of TRPA1 in the brain. Phase 1 clinical trials were initiated following approval from Health Canada to assess safety in healthy volunteers; subsequent Phase 2 studies were planned for painful diabetic neuropathy and allergic asthma[1][3].